POCI — Precision Optics Corporation, Inc.

Precision Optics (POCI) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q2 revenue reached a record $7.4 million, up 64% year-over-year (from $4.5 million) and up 10% sequentially (from $6.7 million).
  • Production Revenue: $6.0 million, a 92% increase year-over-year and a 9% increase sequentially.
  • Engineering Revenue: $1.0 million, down 29% year-over-year but up 47% sequentially.
• Gross Margin: 2.8%, significantly down from 14.2% in Q1 and 23.6% in Q2 2025.
• Net Loss: $1.8 million, compared to a loss of $1.0 million in Q2 2025 and $1.6 million in Q1 2026.
• Adjusted EBITDA: Negative $1.5 million, worsening from negative $0.6 million in the prior year and negative $1.2 million in Q1 2026.
• Cash Position: Approximately $900,000 at the end of December, with bank debt of $1.6 million.

2. Strategic Updates and Business Highlights

• Production Programs: Continued strong performance in key programs:
  • Aerospace program generated $2.7 million in revenue, with expectations to increase to over $3.5 million in Q4.
  • Single-use cystoscope program revenue increased to $2.0 million, with operational improvements anticipated to enhance gross margins.
• Operational Improvements: New COO appointed to address operational challenges; improvements in efficiency and throughput are already being realized.
• Ross Optical Division: Revenue exceeded $1 million for the second consecutive quarter, with a strong backlog indicating a market rebound.
• Product Development: Increased bookings and a growing pipeline in minimally invasive medical devices, with a focus on single-use products.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased to $26 million to $28 million for the fiscal year, up from previous estimates of $25 million.
• Adjusted EBITDA Guidance: Revised to negative $2.5 million to negative $3.0 million, reflecting a delay in margin recovery by about one quarter.
• Expectations: Q3 is anticipated to show improvement over Q2, with Q4 expected to reach positive adjusted EBITDA.

4. Bad News, Challenges, or Points of Concern

• Gross Margins: Continued challenges due to manufacturing inefficiencies, high scrap rates, and yield issues on the cystoscope line.
• Negative EBITDA: The company reported negative adjusted EBITDA for the second quarter, with expectations for further losses in the near term.
• Operational Growing Pains: The rapid scaling of production has led to resource constraints, necessitating leadership changes and operational adjustments.
• Dependency on Key Programs: The reliance on a few major programs for revenue growth poses risks if demand or operational issues arise.

5. Notable Q&A Insights

• Design Revisions: The company is implementing design changes to improve yields on the cystoscope line, with customer approval expected soon.
• Funding Discussions: Advanced negotiations for a new loan facility are underway, with potential grant funding from Massachusetts also being explored.
• Facility Updates: Updates to production facilities are ongoing, with plans for a more substantial overhaul in the coming 6 to 12 months.
• Long-term Investments: Investments in operational infrastructure are expected to yield significant returns as production scales up, supported by a strong demand outlook in both aerospace and medical device markets.

Overall, while Precision Optics has shown impressive revenue growth and operational improvements, challenges remain in achieving profitability and managing production efficiencies. The company is optimistic about future growth driven by strategic investments and a robust pipeline of opportunities.